New eye drops for nearsightedness pass early safety check
NCT ID NCT05470881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety of PRO-201 eye drops (a low-dose atropine solution) in 29 healthy adults aged 18 to 35. The main goal was to see if the drops cause unexpected side effects or light sensitivity. Researchers also checked vision, eye pressure, and comfort. The study is complete, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IIMET Investigación e Innovación en Medicina Traslacional
Guadalajara, Jalisco, 44610, Mexico